The Annual General Meeting in Oasmia Pharmaceutical 2006 was held on September 15. At the meeting Claes Piehl, Julian Aleksov, Peter Ström and Bo Cederstrand were elected as Members of the Board. The Board appointed Bo Cederstrand as Chairman of the Board.
The Meeting decided to adopt the Board’s proposal of private placement.
The Board’s proposal of private placement
The company share capital amounts to SEK 3 100 000 at present, distributed over 31 000 000 shares in total. The Board proposes that the share capital should be increased with SEK 85 131 through an issue of 851 310 new shares of type A, on the terms stated below:
1. The new shares shall be subscribed with deviating preferential rights of the shareholders’ representatives’ rights, by Oasmia SA Luxembourg
2. For every share shall be paid an amount of SEK 41 where SEK 40,90 constitutes premium.
3. Share subscription and off-sets shall be made by October 15 at the latest.
4. The new shares shall be eligible for dividends as of the current fiscal year.
Fees
The Meeting decided that a fee of SEK 25 000 per Member and Board Meeting and SEK 30 000 for the Chairman per Board Meeting shall be paid, with a max amount of SEK 100 000 and SEK 120 000 per year respectively.
Auditors
Öhrling PriceWaterhouseCoopers was appointed as auditors and Bo Åhsell as principal auditor for the mandate period May 1, 2006 to April 30, 2010.